Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

DBV Technologies S.A. American Depositary Shares

DBVT

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Last trade $9.91
Day change -$0.36 (-3.51%)
Day range $9.75 – $10.25
Volume 115,227
Market cap $645M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$645.37M
Price / earnings
—
Price / book
4.34×
Price / sales
167.85×
EV / sales
124.8×
EV / EBITDA
-2.34×

Profitability

Earnings per share
-$3.30
Return on assets
-96.25%
Return on equity
-139.43%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
3.24×
Quick ratio
3.24×
Cash ratio
2.83×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$191.75M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for DBVT, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$1.6M$700K$900K$645K$2.8M$1.5M$800K$511K
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$1.6M$700K$900K$645K$2.8M$1.5M$800K$511K
Selling, general and administrative$19.3M$20.1M$15.3M$12.8M$8.5M$8.9M$5.9M$5.47M
Research and development$47M$31.2M$33.5M$32.89M$28.6M$33.7M$21.5M$18.9M
Total operating expenses$66.3M$51.3M$48.8M$45.7M$37.1M$42.6M$27.4M$24.37M
Operating income-$64.7M-$50.6M-$47.9M-$45.05M-$34.3M-$41.1M-$26.6M-$23.86M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$64.2M-$50.2M-$47.4M-$44.46M-$33.2M-$41.8M-$27.1M-$23.01M
Income taxes$300K$200K$200K$374K$0$100K$0$7K
Net income-$64.5M-$50.4M-$47.6M-$44.83M-$33.2M-$41.9M-$27.1M-$23.02M
Net income attributable to common shareholders-$64.5M-$50.4M-$47.6M-$44.83M-$33.2M-$41.9M-$27.1M-$23.02M
EBITDA-$64.1M-$50M-$47M-$44.36M-$33.5M-$40.4M-$25.6M-$23.22M
Basic earnings per share-$0.14-$0.12-$0.11-$0.24-$0.24-$0.31-$0.26-$0.23
Diluted earnings per share-$0.14-$0.12-$0.11-$0.24-$0.24-$0.31-$0.26-$0.23

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

DBV Technologies annonce le dépôt de sa demande de licence biologique (BLA) auprès de la Food and Drug Administration des Etats-Unis pour le patch VIASKIN® Peanut destiné aux enfants âgés de 4 à 7 ans.

DBV Technologies announced the submission of a Biologics License Application (BLA) to the FDA for its VIASKIN® Peanut patch, designed to treat peanut allergies in children aged 4-7 years. The application is based on positive results from the Phase 3 VITESSE clinical trial, the largest immunotherapy study conducted in this patient population, involving 654 children. DBV has requested priority review of the BLA.

GlobeNewswire Inc.

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

DBV Technologies submitted a Biologics License Application (BLA) to the FDA for VIASKIN® Peanut Patch, a non-invasive epicutaneous immunotherapy treatment for peanut allergies in children aged 4-7 years. The submission is supported by positive results from the VITESSE Phase 3 clinical trial involving 654 children, the largest immunotherapy trial for this population. DBV has requested Priority Review status.

GlobeNewswire Inc.

DBV Technologies annonce le placement d’ADS pour un montant d’environ 50 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq

DBV Technologies announced the placement of approximately $50 million in American Depositary Shares (ADS) with RA Capital Management through its At-The-Market (ATM) program on Nasdaq. The company will issue 18.288 million new ordinary shares at $13.67 per ADS, representing a 5.82% dilution to existing shareholders. The transaction is expected to close on August 3, 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Nov 29, 20241-for-5reverse split
Jun 7, 20241-for-2reverse split